Posted on 26/10/2009 in Medical Company Financials Amgen has posted its third-quarter financial results for 2009.
The company reported adjusted earnings per share of $1.49 (91p) during the timeframe, representing an increase of 21 per cent compared to the $1.23 reported during the third quarter of 2008.
Adjusted net income increased by 16 per cent to $1,518 million in the third quarter of 2009 compared to $1,308 million during the same time last year.
However, the firm experienced a two per cent drop in total revenue generated during the period, the sum dropping to $3,812 million compared to the $3,875 million in the corresponding quarter of 2008.
Kevin Sharer, chairman and chief executive officer of the organisation, said: "We are pleased by the results of clinical studies for denosumab and Vectibix that we recently presented [...] and look forward to making these innovative medicines available to patients in their respective indications."
In other Amgen news this month, the firm revealed that the Food and Drug Administration has requested further information on its postmenopausal osteoporosis treatment Prolia before it considers approving it for marketing and distribution.
Other news stories from 26/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
